Clinical Trial Update: Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients [Phase 3]

View source ↗

Summary

Phase III study evaluating trifluridine/tipiracil with and without bevacizumab in refractory metastatic colorectal cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Refractory Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-12-26